Literature DB >> 26677151

Tumefactive demyelination presenting during bevacizumab treatment.

Claire M Rice1, David Rossiter2, Janev Fehmi2, James C Stevens2, Shelley A Renowden3, Nicki Cohen4, Clare Bailey5, Neil J Scolding1.   

Abstract

We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26677151      PMCID： PMC4691864          DOI： 10.1136/bcr-2015-212173

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  7 in total

1.  Retrobulbar optic neuritis in a bevacizumab-treated patient with metastatic breast cancer.

Authors:  Yan Zhou; Yi Zhang; Xinhua Yang; Linjun Fan; Jun Jiang
Journal:  Breast J       Date:  2012-08-15       Impact factor: 2.431

2.  Tumefactive multiple sclerosis and fingolimod.

Authors:  Jesus Lovera; Nicole Villemarette-Pittman
Journal:  J Neurol Sci       Date:  2014-06-24       Impact factor: 3.181

3.  Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.

Authors:  M A Hellmann; N Lev; I Lotan; R Mosberg-Galili; E Inbar; J Luckman; S Fichman-Horn; M Yakimov; I Steiner
Journal:  J Neurol Sci       Date:  2014-06-17       Impact factor: 3.181

4.  Sera from neuromyelitis optica patients disrupt the blood-brain barrier.

Authors:  Fumitaka Shimizu; Yasuteru Sano; Toshiyuki Takahashi; Hiroyo Haruki; Kazuyuki Saito; Michiaki Koga; Takashi Kanda
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-11-19       Impact factor: 10.154

5.  Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses.

Authors:  Carolyn J MacMillan; Suzanne J Furlong; Carolyn D Doucette; Pei-Lin Chen; David W Hoskin; Alexander S Easton
Journal:  J Neuropathol Exp Neurol       Date:  2012-11       Impact factor: 3.685

6.  An unusual optic disc neovascularization in a case of intermediate uveitis associated with multiple sclerosis.

Authors:  D A Karagiannis; I D Ladas
Journal:  Eur J Ophthalmol       Date:  2008 Nov-Dec       Impact factor: 2.597

7.  The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis.

Authors:  Ellen Iacobaeus; Petra Amoudruz; Mikael Ström; Mohsen Khademi; Lou Brundin; Jan Hillert; Ingrid Kockum; Vivianne Malmström; Tomas Olsson; Emma Tham; Fredrik Piehl
Journal:  PLoS One       Date:  2011-05-06       Impact factor: 3.240
  7 in total
  2 in total

1.  Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.

Authors:  Yoshitsugu Narumi; Ryohei Yoshida; Yoshinori Minami; Yasushi Yamamoto; Shiori Takeguchi; Kohei Kano; Kae Takahashi; Tsukasa Saito; Jun Sawada; Hiroya Terui; Takayuki Katayama; Takaaki Sasaki; Yoshinobu Ohsaki
Journal:  BMC Cancer       Date:  2018-01-24       Impact factor: 4.430

Review 2.  B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders.

Authors:  Jan Traub; Leila Husseini; Martin S Weber
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.